Study to Measure Impact of ProstaScint Imaging in Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

PRINCETON, New Jersey-Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.

PRINCETON, New Jersey—Cytogen Corporation’s ProstaScint (capromabpendetide) is being evaluated in a phase I/II clinical study for its utility inhelping guide intensity modulated radiation therapy (IMRT) for prostate cancer. 

ProstaScint is a radiolabeled monoclonal antibody that targets prostate specificmembrane antigen. In the study, the specific areas of greatest tumor burdenwithin the prostate, identified by the ProstaScint image, will receive boosteddoses of radiation via IMRT.

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content